<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03249909</url>
  </required_header>
  <id_info>
    <org_study_id>Exufiber Ag + 01</org_study_id>
    <nct_id>NCT03249909</nct_id>
  </id_info>
  <brief_title>Evaluation of Exufiber Ag + and Other Gelling Fibre Dressing</brief_title>
  <official_title>A Clinical Investigation to Study the Effect of Exufiber Ag+ and Other Gelling Fibre Dressings on Wound Exudate in Medium to High Exuding Wound</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Molnlycke Health Care AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Molnlycke Health Care AB</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate impact of gelling fiber dressings on handling exudate in medium to high exuding
      wounds
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 14, 2017</start_date>
  <completion_date type="Actual">August 19, 2019</completion_date>
  <primary_completion_date type="Actual">August 19, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The first eligible 50 subjects will be assigned by the investigator to Exufiber Ag+, Subjects 51 to 65 will be assigned to Exufiber, Subjects 66 to 85 will be assigned to Aquacel Ag Extra.
The statistical analysis of the groups treated with Exufiber Ag +, Exufiber or Aquacel Ag Extra will be analysed separately with the same statistical methods.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in exudate from baseline to last visit</measure>
    <time_frame>Total treatment period of 4 weeks (28 days) or earlier if the wound is dry or healed</time_frame>
    <description>Dressing condition (Dry/Moist/Wet/Saturated/Leaking)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Status of the wound and peri-wound skin from baseline to last visit</measure>
    <time_frame>Total treatment period of 4 weeks (28 days) or earlier if the wound is dry or healed</time_frame>
    <description>Evaluated by the Nurse/Investigator Exudate nature (Serous/Serosanguinous/Sanguinous/Purulent/NA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Status of the wound and peri-wound skin from baseline to last visit</measure>
    <time_frame>Total treatment period of 4 weeks (28 days) or earlier if the wound is dry or healed</time_frame>
    <description>Evaluated by the Nurse/Investigator Malodour (None, Slight, Moderate, Strong)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Status of the wound and peri-wound skin from baseline to last visit</measure>
    <time_frame>Total treatment period of 4 weeks (28 days) or earlier if the wound is dry or healed</time_frame>
    <description>Evaluated by the Nurse/Investigator Redness/Irritation under the Primary dressing (Y/N)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Status of the wound and peri-wound skin from baseline to last visit</measure>
    <time_frame>Total treatment period of 4 weeks (28 days) or earlier if the wound is dry or healed</time_frame>
    <description>Evaluated by the Nurse/Investigator Redness/irritation outside the Primary dressing (Y/N)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Status of the wound and peri-wound skin from baseline to last visit</measure>
    <time_frame>Total treatment period of 4 weeks (28 days) or earlier if the wound is dry or healed</time_frame>
    <description>Evaluated by the Nurse/Investigator Maceration under the Primary dressing (Y/N)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate comfort, conformability and acceptability of the dressing</measure>
    <time_frame>Total treatment period of 4 weeks (28 days) or earlier if the wound is dry or healed</time_frame>
    <description>Evaluated by the subject Comfort when wearing the primary dressing (Very Poor/Poor/Good/Very Good/NA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate comfort, conformability and acceptability of the dressing</measure>
    <time_frame>Total treatment period of 4 weeks (28 days) or earlier if the wound is dry or healed</time_frame>
    <description>Evaluated by the subject Ease of mobility while wearing the primary dressing (Very Poor/Poor/Good/Very Good/NA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate comfort, conformability and acceptability of the dressing</measure>
    <time_frame>Total treatment period of 4 weeks (28 days) or earlier if the wound is dry or healed</time_frame>
    <description>Evaluated by the subject Primary dressing remained in place (Very Poor/Poor/Good/Very Good/NA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate comfort, conformability and acceptability of the dressing</measure>
    <time_frame>Total treatment period of 4 weeks (28 days) or earlier if the wound is dry or healed</time_frame>
    <description>Evaluated by the subject Stinging or burning while wearing the primary dressing (Y/N/NA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate comfort, conformability and acceptability of the dressing</measure>
    <time_frame>Total treatment period of 4 weeks (28 days) or earlier if the wound is dry or healed</time_frame>
    <description>Evaluated by the subject Primary dressing, overall experience (Very Poor/Poor/Good/Very Good/NA)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Wounds and Injuries</condition>
  <arm_group>
    <arm_group_label>Dressings</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Exufiber Ag +</intervention_name>
    <description>Gelling Fiber Dressing with Ag</description>
    <arm_group_label>Dressings</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Exufiber</intervention_name>
    <description>Gelling Fiber Dressing without Ag</description>
    <arm_group_label>Dressings</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aquacel Ag Extra</intervention_name>
    <description>Gelling Fiber Dressing with Ag</description>
    <arm_group_label>Dressings</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Informed Consent Form

          -  Both gender ≥ 18 years old

          -  From Medium to High exuding wound

        Exclusion Criteria:

          -  Known allergy or hypersensitivity to any of the treatment dressings

          -  Pregnant or lactating females

          -  Subjects with a target wound that is ≤1 cm2

          -  Subjects with a target wound that is a full thickness burn

          -  Subjects with a target wound that is a full thickness pressure ulcer

          -  Subjects with known immunodeficiency

          -  Subject taking systemic antibiotics for wound infection

          -  Subject were the target wound is located on an infected limb interfered by minimal
             blood flow in the opinion of the investigator

          -  Subject with a target wound with unexplored enteric fistula

          -  Subjects who in the opinion of the investigator, will have problems following the
             protocol

          -  Subjects needing treatment with oxidizing agents such as hypochlorite solutions or
             hydrogen peroxide

          -  Previously enrolled in the present investigation

          -  Inclusion in other ongoing investigations at present that would preclude the subject
             from participating in this investigation as judged by the investigator

          -  Involvement in the planning and conduct of the clinical investigation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Midwestern University</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center For Clinical Research Inc.</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Health Science Center, Inc</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boise VA Medical Center (Boise VAMC) M</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Feinstein Institute for Medical Research</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jobst Vascular Institue (JVI)</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SerenaGroup Research Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>August 6, 2017</study_first_submitted>
  <study_first_submitted_qc>August 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2017</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboxymethylcellulose Sodium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

